drugset / Trial / NCT04024878
NeoVax With Nivolumab in Patients With Ovarian Cancer
Phase 1
Active not recruiting
22 enrolled
Dana-Farber Cancer Institute
United States Department of Defense · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2025-04-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hiltonol | Other / unclassified | — | Subcutaneous |
| Subject | NeoVax | Vaccine | — | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |